Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Visirna Therapeutics

Request full access

Oligonucleotide therapeutics for cardiovascular and metabolic diseases

Huangpu, ChinaFounded 2022Biotech & Life Sciences

About Visirna Therapeutics

Visirna Therapeutics is a biopharmaceutical company specializing in the research and development of oligonucleotide therapeutics. The company was established in April 2022 as a joint venture between Arrowhead Pharmaceuticals (NASDAQ: ARWR) and Vivo Capital, a global healthcare investment firm. This strategic partnership was formed to develop and commercialize a portfolio of RNA interference (RNAi) therapeutics in Greater China, including mainland China, Hong Kong, Macau, and Taiwan.

The venture was launched with an initial investment of $60 million from Vivo Capital. Arrowhead holds a majority equity stake in Visirna, while Vivo Capital holds a minority stake and leverages its network to support recruitment, corporate development, and clinical strategies in the region. The board includes members appointed by both Arrowhead and Vivo Capital, such as Drs. Hongbo Lu and Gaurav Aggarwal from Vivo.

Visirna’s business model is centered on an exclusive licensing agreement for four of Arrowhead's clinical-stage siRNA candidates for treating cardiovascular and metabolic diseases. The company is responsible for all clinical development and commercialization of these licensed products within its designated territory. Its revenue model includes product sales, with Arrowhead being eligible for royalties on net commercial sales. A significant milestone occurred in August 2025 when Visirna sold the Greater China rights for its hypertriglyceridemia candidate, plozasiran, to Sanofi. The deal included a $130 million upfront payment, with potential for up to $265 million in additional milestone payments, demonstrating the value of its licensed assets.

Headquartered in Shanghai, Visirna has advanced its clinical pipeline, notably completing a Phase 3 trial for plozasiran in China for familial chylomicronemia syndrome (FCS), which met its primary and secondary endpoints. Following this success, the company submitted a New Drug Application to China's National Medical Products Administration (NMPA), which was accepted in January 2025 and granted both Breakthrough Therapy and Priority Review designations.

Source: Dealroom company data

Visirna Therapeutics in the Huangpu ecosystem

Live from Dealroom

The Visirna Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later2 investors entered at this stage

Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇨🇳 China90.9%
🇺🇸 United States9.1%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Visirna Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Visirna Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.